Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy
The aim in limited and intermediate stages is to reduce the toxicity by omitting the
subsequent radiotherapy in patients with complete remission after ABVD chemotherapy.
Patients with limited disease receive four cycles, patients with intermediate disease
(according to the criteria of the German Hodgkin Study group, GHSG) receice six cycles of
ABVD. In case of residual mass (> 1.5 cm), additional involved field irradiation is planned.
The aim in advanced disease using BACOPP-D regimen which includes cyclophosphamide,
adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine, is to reduce
the hematological toxicity and the secondary leukemias by omitting etoposide (in comparison
to the BEACOPP escalated regimen). All patients receive eight cycles of the BACOPP-D
regimen. In case of residual mass (> 1.5 cm), additional involved field irradiation is
planned. Additionally, we want to evaluate the CT- and PET-based remission status after
chemotherapy and at final staging.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
- Feasibility and acute toxicity of the therapy
Ralph Naumann, MD
University Clinic "Carl Gustav Carus" Dresden
Germany: Federal Institute for Drugs and Medical Devices